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 ARTICLE OPEN
Targeted disruption of the extracellular polymeric network of
Pseudomonas aeruginosa bioﬁlms by alginate oligosaccharides
Lydia C. Powell1, Manon F. Pritchard1, Elaine L. Ferguson1, Kate A. Powell1, Shree U. Patel1, Phil D. Rye2, Stavroula-Melina Sakellakou3,
Niklaas J. Buurma3, Charles D. Brilliant4, Jack M. Copping4, Georgina E. Menzies 4, Paul D. Lewis4, Katja E. Hill1 and David W. Thomas1
Acquisition of a mucoid phenotype by Pseudomonas sp. in the lungs of cystic ﬁbrosis (CF) patients, with subsequent over-
production of extracellular polymeric substance (EPS), plays an important role in mediating the persistence of multi-drug resistant
(MDR) infections. The ability of a low molecular weight (Mn= 3200 gmol−1) alginate oligomer (OligoG CF-5/20) to modify bioﬁlm
structure of mucoid Pseudomonas aeruginosa (NH57388A) was studied in vitro using scanning electron microscopy (SEM), confocal
laser scanning microscopy (CLSM) with Texas Red (TxRd®)-labelled OligoG and EPS histochemical staining. Structural changes in
treated bioﬁlms were quantiﬁed using COMSTAT image-analysis software of CLSM z-stack images, and nanoparticle diffusion.
Interactions between the oligomers, Ca2+ and DNA were studied using molecular dynamics (MD) simulations, Fourier transform
infrared spectroscopy (FTIR) and isothermal titration calorimetry (ITC). Imaging demonstrated that OligoG treatment (≥0.5%)
inhibited bioﬁlm formation, revealing a signiﬁcant reduction in both biomass and bioﬁlm height (P < 0.05). TxRd®-labelled
oligomers readily diffused into established (24 h) bioﬁlms. OligoG treatment (≥2%) induced alterations in the EPS of established
bioﬁlms; signiﬁcantly reducing the structural quantities of EPS polysaccharides, and extracellular (e)DNA (P < 0.05) with a
corresponding increase in nanoparticle diffusion (P < 0.05) and antibiotic efﬁcacy against established bioﬁlms. ITC demonstrated an
absence of rapid complex formation between DNA and OligoG and conﬁrmed the interactions of OligoG with Ca2+ evident in FTIR
and MD modelling. The ability of OligoG to diffuse into bioﬁlms, potentiate antibiotic activity, disrupt DNA-Ca2+-DNA bridges and
bioﬁlm EPS matrix highlights its potential for the treatment of bioﬁlm-related infections.
npj Bioﬁlms and Microbiomes  (2018) 4:13 ; doi:10.1038/s41522-018-0056-3
INTRODUCTION
Bioﬁlm-associated infections with Gram-negative opportunistic
Pseudomonas sp. represent a formidable challenge in a range of
human diseases, from non-healing skin wounds to chronic
respiratory disease. In cystic ﬁbrosis (CF), the colonisation of the
lung with Pseudomonas aeruginosa is associated with chronic
inﬂammation and deterioration of lung function, leading to a
signiﬁcant increase in morbidity and mortality.1 Longitudinal
studies in CF have demonstrated that initial pseudomonal
colonisation occurs by wild-type (non-mucoid) P. aeruginosa. With
disease progression and adaptation to the lung environment, P.
aeruginosa may acquire a mucoid phenotype, with over-
production of the exopolysaccharide alginate,2 arising predomi-
nantly from mutations in mucA.3
Within bioﬁlm structures, bacteria exhibit increased resistance
to conventional antibiotic therapies (up to 103-fold)4,5 via a range
of indirect and direct mechanisms. These factors include
resistance to host-mediated innate and adaptive immune
responses,6 sequestration of antibiotics in the bacterial periplasm,7
reduced bacterial metabolic activity8 and development of
associated persister cells.9 Speciﬁc genetic changes may include
activation of stress responses e.g., efﬂux-pumps,10 and the
density-dependent expression of quorum-sensing (QS) signalling
molecules.11 These factors confer signiﬁcant ‘ﬁtness’ advantages
for bioﬁlm cells when compared with their planktonic-grown
isogenic counterparts.
Although imprecisely deﬁned, bacterial extracellular polymeric
substance (EPS) consists mainly of polysaccharides, proteins, lipids
and nucleic acids (RNA and extracellular DNA; eDNA) and
facilitates bioﬁlm formation and maturation.12,13 The effects of
eDNA on formation and maturation are mediated, in part, via its
direct interaction with calcium (Ca2+) within the bioﬁlm, which
induces bacterial aggregation via “cationic bridging”.14 Extracel-
lular Ca2+ also plays an important role within the bioﬁlm in
modifying bacterial cell-surface charge, facilitating cellular aggre-
gation and the adherence of bacteria to material/tissue surfaces15
by positively charged Ca2+ ions overcoming the electrostatic
repulsion between negatively-charged bioﬁlm components. P.
aeruginosa can exhibit distinct differences in the composition of
their EPS bioﬁlm matrices; the precise composition being strain-
dependent and age-dependent and also strongly inﬂuenced by
environmental conditions e.g., pH, oxygen tension, and nutrient
availability.12,16 Studies have previously attempted to deﬁne and
quantify the EPS component of pseudomonal bioﬁlms17–20 and
study their distribution in bioﬁlm assembly via selective stain-
ing.20–23
Non-mucoid P. aeruginosa strains produce two important
polysaccharides which are involved in bioﬁlm formation namely,
Pel (a cationic exopolysaccharide composed of 1–4 linked
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galactosamine and glucosamine sugars)24 and Psl (a penta-
saccharide composed of D-glucose, D-mannose and L-rhamnose).25
In non-mucoid strains, Psl/Pel predominates in the bioﬁlm matrix,
while alginates predominate in bioﬁlms produced by mucoid
strains.26 The alginates of mucoid Pseudomonas sp. are anionic,
linear polymers composed of β-D-mannuronic acid (M) and α-L-
guluronic acid (G) with a high molecular weight (Mw;
120–480 kDa).27 The persistence of pseudomonal infection within
the CF lung has, in part, been hypothesised to relate to the
emergence of the multi-drug resistant (MDR) mucoid pheno-
type,6,28 with over-production of the alginate exopolysaccharide
matrix providing structural integrity to bacterial microcolonies
within the diseased lung.29 The currently available treatments for
pseudomonal infections in the CF lung (via inhaled, oral, or
intravenous antibiotic therapies) unsurprisingly have limited
efﬁcacy in total bioﬁlm eradication. A large unmet clinical need
therefore exists for effective antibioﬁlm therapies in human
disease.30
A number of antibioﬁlm therapeutic strategies have been
employed. EPS disruption strategies (including the use of alginate
lyase) have, despite advances in enzyme engineering, so far
proved ineffective.31 More recently, products derived from the
marine environment have been investigated for antimicrobial/
anti-bioﬁlm activity e.g., furanones from the red algae Delisea
pulchra.32,33 However, none of these potential therapeutic
approaches are as yet in clinical use.
Work in our laboratory has demonstrated the ability of a low
molecular weight antimicrobial agent, OligoG CF-5/20, (an alginate
oligosaccharide derived from the marine algae Laminaria hyper-
borea with a G content >85%), to inhibit Gram-negative bacterial
growth and potentiate (synergistically enhance) conventional
antibiotics against bacteria in planktonic systems (by up to 512-
fold) in the non-mucoid P. aeruginosa PAO1.34 Recent in vitro
studies have also demonstrated the ability of OligoG to potentiate
the activity of colistin against mucoid CF isolate P. aeruginosa
NH53788A35 and induce in vivo bioﬁlm disruption in a murine
lung infection model.36 We hypothesised that the observed
potentiation of antibiotics against mucoid P. aeruginosa
NH57388A was, in part, a direct result of the interaction of OligoG
with the EPS component of the bacterial bioﬁlm. To test this
hypothesis in vitro, we studied the interaction of OligoG with EPS,
and speciﬁcally eDNA, in pseudomonal bioﬁlms using
ﬂuorescently-labelled oligomers and nanoparticle diffusion to
directly quantify these interactions.
RESULTS
OligoG inhibits in vitro mucoid bioﬁlm formation
Scanning electron microscopy (SEM) imaging demonstrated a
dose-dependent reduction in P. aeruginosa NH57388A bacterial
density and bioﬁlm growth in the presence of OligoG (Fig. 1a). This
bioﬁlm inhibition was quantiﬁed and conﬁrmed with COMSTAT
analysis of confocal laser scanning microscopy (CLSM) z-stack
images, showing that OligoG (≥2%) signiﬁcantly disrupted bioﬁlm
growth in a dose-dependent manner, exempliﬁed by decreased
mean bioﬁlm bio-volume and thickness and increased roughness
coefﬁcient following treatment (Fig. 1b, c; P < 0.05). CLSM imaging
also revealed that the presence of OligoG was associated with
dose-dependent bacterial aggregation, which was particularly
evident at concentrations ≥0.5%.
OligoG disrupts established in vitro mucoid bioﬁlms
Growth of P. aeruginosa NH57388A for 24 h generated well-
deﬁned 3-dimensional bioﬁlm structures (mean thickness of
17.8 ± 5.2 µm). CLSM imaging and COMSTAT analysis revealed
that the effect of OligoG on these established bioﬁlms was time-
dependent (Fig. 2). Although treatment for 1 h appeared to have
no effect on bioﬁlm structure (Fig. S1), 4 h treated bioﬁlms showed
a dose-dependent reduction in bioﬁlm thickness at OligoG
concentrations ≥2%, and a signiﬁcant increase in roughness
coefﬁcient at OligoG concentrations ≥6% (P < 0.05; Fig. 2a). After
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Fig. 1 Effect of OligoG on inhibition of mucoid bioﬁlm formation: Imaging and quantiﬁcation of P. aeruginosa (NH57388A) bioﬁlms grown for
24 h at 37 °C in MH broth ± OligoG (0.5%, 2% & 6%). a SEM imaging of bioﬁlms (Scale bar, 10 µm). b CLSM 3D imaging (aerial view) of LIVE/
DEAD® staining of bioﬁlms (Scale bar, 20 µm). c COMSTAT image analysis of the corresponding bioﬁlm CLSM z-stack images. *P <
0.05 signiﬁcance was determined by comparison to the untreated control. Error bars represent the standard deviation of the data set (n= 3)
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24 h treatment there was a more marked reduction in bioﬁlm bio-
volume and a signiﬁcantly decreased bioﬁlm thickness with
increased OligoG concentrations (P < 0.05; Fig. 2b). These effects
were also dose-dependent, with signiﬁcantly increased roughness
coefﬁcients and a decrease in the numbers of non-viable bacterial
cells observed with increasing OligoG concentration in the treated
samples (P < 0.05; Fig. 2b).
Texas red (TxRd®) labelling studies demonstrate diffusion of the
oligomer into mucoid bioﬁlms
OligoG was labelled with Texas red (TxRd®) to facilitate visualisa-
tion of OligoG within the bioﬁlms (Fig. S2a, b, c). CLSM images of
OligoG (≥0.5%) treated P. aeruginosa (NH57388A) bioﬁlm forma-
tion (24 h) (Fig. S3a) and bioﬁlm disruption (Fig. S3b) showed
TxRd®-associated ﬂuorescence was distributed throughout the
whole bioﬁlm structure. Furthermore, CLSM images emphasised
the bioﬁlm inhibitory and disruptive properties of TxRd®-OligoG,
displayed by a signiﬁcant dose-dependent decrease in mean
bioﬁlm bio-volume and increase in roughness coefﬁcient with
increasing TxRd®-OligoG concentrations for both bioﬁlm forma-
tion (Fig. S4a) and bioﬁlm disruption (Fig. S4b) assays (P < 0.05).
Although un-conjugated “free” TxRd® dye was shown to
penetrate to the base of the bioﬁlm, this was not associated with
alteration of bioﬁlm architecture or bacterial aggregation (see Fig.
S4c). In contrast, penetration of the labelled OligoG to the base of
established bioﬁlms was associated with bacterial aggregation
(Fig. S2c). Analysis of the supernatant by size exclusion
chromatography demonstrated that there was no detectable free
TxRd® present, thereby conﬁrming that TxRd® was not released
from OligoG during the experiment (Fig. S2b; TxRd® eluted at
>5.5 ml).
OligoG does not cause an increase in planktonic cell numbers after
treatment of established bioﬁlms
To determine the effect of the oligomers on possible dispersal of
planktonic cells following treatment of established (24 h) bioﬁlms,
analysis of the cell supernatant was performed. This revealed that
the observed decrease in bioﬁlm bio-volume and thickness (Fig.
2b) was not directly related to increased numbers of planktonic
cells in the growth medium following 24 h OligoG treatment.
Instead, there was a dose-dependent decrease in planktonic cells
that was signiﬁcant at 6% OligoG (P < 0.05; see Fig. S5),
presumably as a direct result of reduced growth following
treatment.
OligoG disrupts EPS within the mucoid bioﬁlm matrix
P. aeruginosa NH57388A bioﬁlms were stained to visualise
different components of the bioﬁlm using SYPRO® Ruby Red
(proteins; Fig. S6), Alexa Fluor 633-labelled Concanavalin A (α-D-
glucose and α-D-mannose; ConA) and TOTO-1 (eDNA) (Fig. 3a,
b).20,21 SYPRO® Ruby Red staining demonstrated a dose-
dependent inhibition of bioﬁlm matrix formation (speciﬁcally the
protein component of the bioﬁlm) with increasing OligoG
concentration (see Fig. S6). However, this same trend was not
observed in ﬂuorescence intensities quantiﬁed from CLSM images
achieved using ConA and TOTO-1 staining (Fig. 3a), which
revealed no signiﬁcant changes in ﬂuorescence intensity (for
either polysaccharides or eDNA respectively) during bioﬁlm
formation following OligoG treatment (Fig. 3c). Instead, from the
CLSM images of bioﬁlm formation, there appeared to be a change
in the distribution of the ConA staining following OligoG
treatment (>0.5%), with a trend towards smaller clusters of
ConA-stained EPS components (polysaccharides) (Fig. 3a). In
contrast, CLSM images (Fig. 3b) and corresponding ﬂuorescence
intensity measurements of P. aeruginosa NH57388A 24 h estab-
lished bioﬁlms treated with OligoG, revealed a signiﬁcant dose-
dependent reduction in the ﬂuorescence intensity of both ConA
and TOTO-1 staining following treatment (P < 0.05), indicating
bioﬁlm disruption through reduction in both the polysaccharides
and eDNA components of the bioﬁlm matrix (Fig. 3d).
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Fig. 2 Effect of OligoG on disruption of mucoid established bioﬁlms: CLSM 3D imaging (side view) with LIVE/DEAD® staining of P. aeruginosa
(NH57388A) bioﬁlms grown for 24 h at 37 °C in MH broth followed by 4 or 24 h OligoG treatment (0.5, 2 & 6%) (Scale bar, 15 µm) with COMSTAT
image analysis of the corresponding bioﬁlm CLSM z-stack images. Treatment times a 4 h. b 24 h. *P < 0.05 signiﬁcance was determined by
comparison to the untreated control. Error bars represent the standard deviation of the data set (n= 3)
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OligoG treatment increases nanoparticle diffusion within bioﬁlms
A Transwell® bioﬁlm diffusion assay was developed employing
ﬂuorescent nanoparticles to measure particle diffusion through
bioﬁlms, treated with/without OligoG for 4 h (Fig. 4a). OligoG
treatment (2%) of bioﬁlms increased the diffusion of ﬂuorescent
nanoparticles at 1 h and 2 h incubation after nanoparticle addition
(Fig. 4b, c), which was signiﬁcantly different at the 1 h time point
(P < 0.05).
OligoG acts synergistically with the antibiotic erythromycin and
tobramycin against bioﬁlms
Minimum inhibitory concentration (MIC) assays and CLSM imaging
were performed to visualise the potential synergy between OligoG
and the antibiotics erythromycin and tobramycin. The MIC for
erythromycin was reduced four-fold against the P. aeruginosa
NH57388A, from 128 μgml−1 (0% OligoG) to 32 μgml−1 after
treatment with 6% OligoG, whilst the MIC for tobramycin against
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Fig. 3 Effect of OligoG on the EPS components of mucoid bioﬁlms. 3D CLSM imaging of P. aeruginosa (NH57388A) bioﬁlms stained with ConA
(EPS polysaccharides, red) and TOTO-1 (eDNA, green; scale bar, 8 µm) in a bioﬁlm formation assay, where bioﬁlms are grown for 24 h in MH
broth ± OligoG (0.5%, 2% & 6%) and b the bioﬁlm disruption model where bioﬁlms grown for 24 h in MH broth, followed by 24 h treatment of
OligoG (0.5%, 2% & 6%). Corresponding mean ﬂuorescence intensities (arbitrary units ×106) achieved from CLSM 3D imaging of the c bioﬁlm
formation assay and the d bioﬁlm disruption assay. *P < 0.05 signiﬁcance was determined by comparison to the untreated control. Error bars
represent the standard deviation of the data set (n= 3)
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P. aeruginosa NH57388A remained unchanged with OligoG
treatment (1 μgml−1). CLSM images also showed increased
bioﬁlm disruption and increased numbers of non-viable cells in
bioﬁlms treated with 2% OligoG and 128 μgml−1 (MIC value)
erythromycin, in contrast to the erythromycin-only treated control
(see Fig. S7). In bioﬁlms treated with 2% OligoG and 1 μgml−1
(MIC value) tobramycin whilst disruption of the treated bioﬁlms
was also evident, no similar increase in non-viable cells was
observed (Fig. S7).
Molecular dynamics (MD) simulations demonstrated contrasting
interactions of OligoG with calcium and DNA
MD modelling demonstrated the ability of Ca2+ ions to rapidly
bind pseudomonal DNA (in <1 ns; Fig. 5a), illustrating clearly how
Ca2+-DNA-Ca2+ “bridges” may be formed in vivo (between
individual DNA molecules in ~ 60 ns; Fig. 5b). Ca2+ binding
appeared to initiate the formation of these bridges, and once
formed, the bond remained stable, while further bridging
occurred. Addition of OligoG (DPn 16) in these models (Fig. 5c),
demonstrated its interaction with the Ca2+ ions both present in
the Ca2+-DNA-Ca2+ “bridges” and its rapid sequestration of free
Ca2+ ions. The simulation revealed the ability of the oligosacchar-
ide to invade the structural assembly and disrupt these existing
bridges between adjacent DNA molecules, resulting in the
formation of stable DNA-Ca2+-OligoG-Ca2+-DNA bridged com-
plexes (Fig. 5d). The simulations, in which “free Ca2+” ions were
removed, revealed the limited ability of OligoG to remove Ca2+
molecules already bound to DNA.
OligoG exhibits contrasting molecular interactions with calcium
and DNA
The interaction of the alginate oligosaccharide, OligoG, with Ca2+
ions was also readily demonstrated by fourier transform infrared
spectroscopy (FTIR; Fig. 6a) being evident in peak-shift, most
markedly in the “glycogen-rich” region of the spectrum
(1200–900 cm−1; Fig. 6b and Fig S8a). The lack of novel peaks
suggested that Ca2+ ions interact with OligoG via speciﬁc
molecular interactions, via electrostatic and/or ionic interactions,
inﬂuencing the stretching/bending moments of the C–O bonds
characteristic of this region. By contrast, FTIR spectral analysis
failed to demonstrate any major differences in the OligoG spectra
following DNA treatment, with little change in peak positions
(Fig. 6b).
OligoG does not show instantaneous interactions with DNA
The interactions of OligoG with DNA in the presence of 1 and
5mM Ca2+ were studied using isothermal titration calorimetry
(ITC). The heat effects for dilution of OligoG in the presence of
Ca2+ were not constant, indicating self-aggregation of OligoG. In
the presence of 1 mM Ca2+, the observed dilution heat effects
were endothermic (Fig. 6c) whereas they were exothermic in the
presence of 5 mM Ca2+ (Fig. 6d). In the presence of 5 mM Ca2+ the
dilution heat effects showed stronger variation than in the
presence of 1 mM Ca2+, suggestive of synergy in the process of
calcium binding to alginates at higher Ca2+ concentrations.
Comparison of the molar heat effects for dilution of OligoG into
buffer with the molar heat effects for titration of OligoG into DNA
however, showed no signiﬁcant differences. Hence, in the
presence of 1–5mM Ca2+, interactions between DNA and OligoG
were either too weak or occurred on too long a timescale (longer
than tens of seconds) to be detected using ITC. Increasing the
DNA concentration to 10 mM DNA in the presence of both 1 and
5mM Ca2+ demonstrated the same trend in the presence of
OligoG (Fig. S8b and c).
DISCUSSION
Bacterial bioﬁlms represent a considerable challenge for anti-
microbial therapy. Therefore, in the development of novel
therapeutic approaches, it is important to determine the extent
to which such new drugs can penetrate the bioﬁlm and disrupt
the components of the EPS.37 The observed inhibition of
pseudomonal bioﬁlm formation in the presence of OligoG is in
accord with previous in vitro AFM force-measurement and
rheological studies, where OligoG induced discrete mechanical
alterations within bioﬁlms.38 Also, a recent in vivo murine lung
infection model study36 conﬁrmed that OligoG disrupted bioﬁlm
formation in a dose-dependent manner. The mechanisms by
which these changes may occur in developing bioﬁlms, may relate
to several previously-described effects of the alginate on
planktonic P. aeruginosa PAO1 including: binding to the Gram-
negative bacterial cell surface, forming microbial aggregate
complexes with OligoG,39 inhibition of growth,34 decreased
bacterial surface attachment,40 modulation of surface charge
(zeta potential) and reduction of bacterial motility.39 All of these
effects could readily modify bioﬁlm formation. However, these
mechanisms would not affect the marked disruption evident in
the dense (approximately 20 μm thick), established (24 h)
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NH57388A bioﬁlms. The dose-dependent disruption of established
bioﬁlms with oligomer treatment was however, clearly evident
from the COMSTAT analysis;41 characterised by marked decreases
in bioﬁlm bio-volume (up to 3-fold reduction) and mean thickness.
A potential mechanism by which anionic low Mw oligomers
might act in established bioﬁlms is via disruption of the EPS
components of the bioﬁlm matrix.42 We hypothesised that gross,
dose-dependent bioﬁlm disruption would necessitate the effec-
tive diffusion of OligoG throughout the whole bioﬁlm matrix. The
use of labelled oligomers allowed us to study the ability of OligoG
to diffuse into the complex, “branching” mesh of the hydrated
bioﬁlm EPS. TxRd®-labelled OligoG could be seen throughout the
bioﬁlm network, both during bioﬁlm formation (formed in the
presence of treatment) at OligoG concentrations as low as 0.5%,
and also after treatment of established bioﬁlms, demonstrating
effective diffusion of the negatively-charged oligomers into the
bioﬁlm structure and their ability to induce bacterial aggregation
(in contrast to the TxRd® control). This study conﬁrmed that the
efﬁcacy of OligoG was not bioﬁlm surface-restricted and more-
over, that TxRd®-labelling did not impair the anti-bioﬁlm effects of
OligoG.
The importance of eDNA in pseudomonal bioﬁlm architecture
has been demonstrated in directing both cell-surface attach-
ment43,44 and providing mechanical stability.14 Within the
diseased lung, eDNA may be derived from autolysis of the bioﬁlm
bacteria and host-derived immune cells.21 No apparent difference
in the quantity of eDNA was observed in bioﬁlms formed in the
presence of OligoG. Therefore, the ability of OligoG to inhibit
bioﬁlm formation may be related to the previously described
activity of the oligomers on planktonic Gram-negative bacteria,
such as P. aeruginosa PAO1, where treatment modiﬁed bacterial
growth,34 cell-surface charge,39 and inhibited bacterial attach-
ment.40 In contrast, imaging studies of established bioﬁlms
demonstrated the ability of OligoG (≥2%) to signiﬁcantly reduce
bioﬁlm eDNA. Interestingly, the previously demonstrated ability of
the oligomers to modify pilE gene expression and swarming
motility in P. aeruginosa,39 and induce dose-dependent reductions
(>0.2%) in non-mucoid pseudomonal QS signalling35,45 suggests
that modulation of QS signalling within the bioﬁlm environment
may also play a direct role in mediating the observed changes in
bioﬁlm architecture and eDNA.
Lectin staining combined with CLSM imaging provided not only
a visual demonstration of the effects of OligoG on the EPS bioﬁlm
matrix, but also enabled quantiﬁcation of the structural changes in
the bioﬁlm matrix. ConA staining with CLSM imaging demon-
strated that the oligomers morphologically altered the distribution
of EPS polysaccharides during bioﬁlm formation and also
following treatment of established bioﬁlms; ﬂuorescence intensity
measurements revealed signiﬁcantly decreased polysaccharides in
the oligomer-treated established bioﬁlms. The glucose-rich poly-
saccharide Pel (a cationic EPS component produced during P.
aeruginosa bioﬁlm formation) is involved in cell-to-cell interac-
tions,17 and has recently been demonstrated to ionically cross-link
eDNA within the bioﬁlm matrix,24 whilst the mannose-rich Psl (a
key constituent of bioﬁlm scaffolding) mediates both cell-surface
and cell–cell interactions.18–20 Kundukad et al.46 recently demon-
strated that differences in Psl concentration (occurring with
bioﬁlm maturation) resulted in altered mechanical properties of
bioﬁlms. Moreover, it has been hypothesised that pseudomonal
rugose small-colony variants, expressing increased levels of Pel
and Psl, might play an important role in mediating bacterial
persistence following prolonged antibiotic treatment, within the
CF lung.47 Pseudomonal alginates are also key components of the
bioﬁlm matrix in the diseased CF lung and contribute to the thick,
viscous mucus.48 Mucoid strains of P. aeruginosa typically produce
high-Mw (>15 kDa) naturally acetylated alginates13 which lack
consecutive G-residues and contribute to the mechanical strength
of the bioﬁlm, via chelation of divalent cations (e.g., Ca2+ and Mg2
+).49 Due to the structural importance of the EPS in maintaining
bioﬁlm physiology, numerous strategies have been developed in
an attempt to effect EPS disruption including the use of alginate
lyase, DNase and hydrolase-based approaches.30,50,51 OligoG may
also modify the structure of EPS via its ability to bind divalent
cations, e.g., Ca2+ and Mg2+, which are involved in regulating EPS
and eDNA interactions within the bioﬁlm scaffold;43,48 Ca2+ also
appearing to play an important role in the switch in P. aeruginosa
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from acute to chronic virulence.52 Chelation by OligoG results
from the Ca2+-binding afﬁnity of the conformational arrangement
of the G-block co-polymer. Alginates, such as OligoG, are known to
interact with Ca2+ in a dose-dependent process, displaying auto-
cooperativity53–56 and the recently observed ability of OligoG to
modify the assembly of the dense CF intestinal mucus has been
hypothesised to occur via chelation of Ca2+.57–59 Bacterial
polysaccharides, Ca2+ and eDNA are key, inter-related compo-
nents of bioﬁlms which direct assembly, architecture and
resistance to therapy.14,58 Disruption of these important bioﬁlm
matrix components by the negatively-charged OligoG could have
contributed to the observed changes in bio-volume and bioﬁlm
thickness in both bioﬁlm formation and treated established
bioﬁlms. It is important to note however, that ConA binding is
not solely restricted to α-D-glucose and α-D-mannose; Con A may
also label high-molecular weight bacterial-derived alginate block
co-polymers, within the bioﬁlm structure.22
Previously, Ca2+-mediated interactions between the lipopoly-
saccharides (LPS) of Gram-negative bacteria and OligoG60 and
DNA61 have been demonstrated. Instead here, we studied the
potential interactions between OligoG and DNA mediated by Ca2+
that could occur within pseudomonal bioﬁlms. MD simulations
suggested that OligoG might effectively disrupt the assembly of
new DNA-Ca2+-DNA bridges in bioﬁlm development, in keeping
with the CLSM studies. The ability of OligoG to “invade” these
established DNA-Ca2+-DNA networks was supported by the
effective diffusion of ﬂuorescently-labelled oligomers into 24 h
bioﬁlms. This proposed invasion/disruption may be reﬂected in
the previously altered viscoelastic properties of OligoG-treated
pseudomonal bioﬁlms.38 Furthermore, the MD simulations sug-
gested that, once bound, the “free end” of the oligomer retained
the ability to bind free-Ca2+ (and adjacent OligoG molecules). This
ﬁnding may explain the dose-dependent aggregation in the
treated samples observed here, and in previous studies.39 The ITC
experiments (at higher Ca2+ concentrations) also reﬂected this
Ca2+-dependent, self-aggregation of OligoG.
The MD simulations suggested the importance of the interac-
tions with Ca2+, rather than direct interactions of the OligoG with
the DNA in our bioﬁlm models. It must be noted however, that the
simulation was designed to study Ca2+-DNA interactions, (and
other divalent cations e.g., Mg2+ which are also bound by the
oligosaccharides) which may be modiﬁed in vivo. FTIR showed a
lack of apparent molecular interaction between OligoG and DNA.
Furthermore, ITC demonstrated that, even in the presence of
calcium, OligoG and DNA do not interact instantaneously,
suggesting that the bioﬁlm-disrupting effects of OligoG are not
the result of a (rapid) Ca2+ mediated interaction between OligoG
and eDNA and would not induce immediate bioﬁlm destabilisa-
tion. The lack of instantaneous interactions between OligoG and
DNA is in agreement with the observed time-dependent
disruption of treated established bioﬁlms. Whilst all of these
in vitro experiments do not reproduce the complex relationship
that exists between eDNA, Ca2+ and bacterial polysaccharides
within bioﬁlms in vivo, they are useful models to study potential
interactions.
Elevated levels of cations (up to 120 mg l−1 Ca2+) are evident
locally in the diseased lungs of CF patients and have been
hypothesised to contribute to the severity of disease.62 Several
studies have consequently considered the possible therapeutic
utility of chelating agents to enhance bioﬁlm disruption and
facilitate antibiotic potentiation in vitro.63 In contrast to “broad-
spectrum” chelating agents such as EDTA, OligoG lacks toxicity
issues. Hence in terms of CF treatment, the effect of OligoG on
both divalent cations and eDNA is highly beneﬁcial for these
patients, in whom pulmonary levels of Ca2+ and Mg2+ may be
elevated.
OligoG has been proven to be safe for inhalation therapy and
has been shown to alter the viscoelasticity of CF sputum.64 OligoG
has been demonstrated to not only reduce bacterial load within
bioﬁlm structures, but also to target and disrupt the EPS matrix of
established bioﬁlm architecture. Conceptually, this disruption of
established bioﬁlms may facilitate penetration of the bioﬁlm-
coated lung surface, which is an effective barrier to the delivery of
pharmacotherapy and gene-therapy across the lung-surface in
disease.37 To test this, we utilised a ﬂuorescent, particle-diffusion
model using bioﬁlms in a Transwell® system, which has recently
been used to study ﬂuorescent particle permeation through
mucus.65 Negatively-charged particles were employed since the
EPS matrix of bioﬁlms also has an overall negative net charge66
and a number of negatively-charged antibiotics may also be used
in the treatment of Gram-negative bioﬁlm infections e.g.,
ciproﬂoxacin.25,67 The Transwell® assay, developed here to model
diffusion through bacterial bioﬁlms, has the advantage of
measuring the ‘bulk’ properties of the entire bioﬁlm. In this
model, it was clear that the dose-dependent increase in bioﬁlm
disruption and decreased thickness evident from the CLSM
imaging was also reﬂected in increased particle diffusion.
Although signiﬁcantly increased diffusion was observed in the
Transwell® assay, the standard deviations were relatively high,
indicating possible pore-blockage68 and/or the non-uniformity of
bioﬁlm disruption observed in the CLSM imaging. These experi-
ments used oligomer concentrations of ≤2% to facilitate rinsing of
the bioﬁlms. Despite these issues, the results revealed the utility of
the Transwell® particle diffusion assay to model the efﬁcacy of
anti-bioﬁlm strategies.
Baker et al.69 recently demonstrated that the bioﬁlm EPS-
disrupting ability of glycoside hydrolases (PelAh and PslGh) was
accompanied by potentiation of the antibiotic colistin. Workers
have recently demonstrated ability of OligoG to synergistically
enhance the activity of colistin against P. aeruginosa NH57388A in
minimum bioﬁlm eradication concentration assays.36 We showed
here that OligoG also potentiated the antibioﬁlm activity of the
macrolide antibiotics, erythromycin and tobramycin against P.
aeruginosa NH57388A bioﬁlms. The results were contrasting, and
not as marked in tobramycin, which may reﬂect, in part, the
interaction of the anionic OligoG, with the polycationic tobramy-
cin. Interestingly, in addition to disruption of the EPS, the ability to
potentiate antibiotic activity against bioﬁlms described here may
also be mediated via the ability of OligoG to modify pseudomonal
motility,34 where Chua et al.70 recently demonstrated the
importance of motility in the acquisition of colistin resistance
within pseudomonal bioﬁlm communities.
These studies demonstrate the effects of the inhaled alginate
oligomer therapy, OligoG, in impairing the formation and
facilitating disruption of mucoid bioﬁlms. Whilst the mechanisms
of disruption of bioﬁlm EPS matrix and the modiﬁcation of eDNA
assembly in the bioﬁlms may be regulated indirectly (via QS
signalling) these studies demonstrate the mechanistic importance
of direct interaction of OligoG with Ca2+ and the resultant
modiﬁcation of intercellular bridges within the Ca2+- DNA bioﬁlm
mesh.
The direct and indirect anti-bioﬁlm effects, coupled with the
safety and tolerability of OligoG CF-5/20 may have potential
clinical utility in the management of bioﬁlm-related Gram-
negative infections. Phase IIb clinical studies are ongoing in CF
patients (www.ClinicalTrials.gov [NCT02157922], [NCT02453789]).
MATERIALS AND METHODS
Alginate oligosaccharide synthesis (OligoG)
OligoG CF-5/20 was produced from the stem of the brown seaweed
Laminaria hyperborea and puriﬁed and fractionated as previously
described.32 This resulted in a low molecular weight (mean Mn 3200 g
mol−1) alginate oligomer possessing a high guluronate content (>85%)
with a degree of polymerisation [DPn] of 16.
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Bacterial strains and media
A mucoid, CF P. aeruginosa clinical isolate (NH57388A) was used in this
study.71–73 Bacterial colonies were grown on blood agar no.2 (BA; Lab M)
supplemented with 5% horse blood. Overnight cultures were grown in
tryptone soya broth (TSB; Lab M) at 37 °C, with shaking. Cultures were
adjusted to 107 cfu ml−1 (~OD600 0.05)
74 before use in the following
experiments.
Effect of OligoG as a treatment to inhibit bioﬁlm formation (SEM)
Mueller Hinton (MH) broth (Lab M) ± 0.5%, 2% or 6% OligoG (w/v) was
prepared in a 12-well plate (Greiner Bio-One, Stonehouse, UK) containing
ThermanoxTM slides (Agar Scientiﬁc), followed by an inoculum using a
1:100 dilution of the P. aeruginosa (NH57388A) overnight culture, and
incubated at 37 °C with gentle rocking for 24 h. The supernatant was then
removed and bioﬁlms ﬁxed with 2.5% (v/v) glutaraldehyde for 1.5 h.
Following washing (x4) with dH2O, the ﬁxed bioﬁlms were covered with
1ml dH2O, frozen and then freeze-dried. Imaging was performed using
Hitachi S4800 SEM without sputter coating.
Effect of OligoG as a treatment to inhibit bioﬁlm formation (CLSM)
For CLSM imaging, P. aeruginosa NH57388A bioﬁlms were grown in
Whatman 96-well glass-bottomed plates in MH broth ± 0.5, 2, or 6% OligoG
(or TxRd®-labelled OligoG). A 1:10 inoculum of the P. aeruginosa
(NH57388A) overnight culture was used and plates were incubated at
37 °C for 24 h.
Effect of OligoG as a treatment to disrupt established bioﬁlms and
to potentiate the effect of erythromycin and tobramycin
P. aeruginosa NH57388A bioﬁlms were grown in Whatman 96-well glass-
bottomed plates in MH broth using a 1:10 (v/v) inoculum of overnight
culture and plates were incubated at 37 °C for 24 h prior to treatment. Half
the supernatant was then carefully removed and replaced with fresh MH
broth ± OligoG (or TxRd®-labelled OligoG). The ﬁnal concentrations of
OligoG used were 0.5, 2, and 6% (v/v). The samples were then incubated at
37 °C at each time point (1, 4, and 24 h) before imaging. For the
erythromycin and tobramycin potentiation experiments, half the super-
natant was removed after 24 h bioﬁlm growth and replaced with MH
broth ± 2% OligoG and 128 µgml−1 (MIC value) erythromycin (ﬁnal
concentration; v/v) or 1 µgml−1 (MIC value) tobramycin (ﬁnal concentra-
tion; v/v) before a further 24 h incubation at 37 °C.
Texas Red (TxRd®)-labelling of OligoG and conjugate
characterisation
To follow the fate of OligoG during bioﬁlm inhibition and disruption via
CLSM, conjugation to a ﬂuorescent dye was utilised. OligoG was labelled
with TxRd® cadaverine (molecular weight 690.87 gmol−1) using 1-ethyl-3-
[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC) and N-
hydroxysulfosuccinimide (sulfo-NHS) as zero-length crosslinking agents
(Fig. S2a; see supplementary information for full methodology and control
experiments conducted).
Selective staining and CLSM imaging
Bioﬁlm supernatants were carefully removed before staining. For the
OligoG bioﬁlm assays, the bioﬁlms were stained with LIVE/DEAD®
(BacLightTM Bacterial Viability Kit, Molecular ProbesTM) for 10min, prior
to imaging for bacterial visualisation. For the TxRd®-OligoG bioﬁlm assays,
the bioﬁlms were stained with SYTO® 9 for 10min prior to CLSM imaging.
For visualisation of protein content, bioﬁlms were stained with FilmTra-
cerTM SYPRO® Ruby Bioﬁlm Matrix stain (Molecular ProbesTM; 4 h
incubation) or stained with TOTO-1 (Molecular ProbesTM; 20 min incuba-
tion) in combination with Concanavalin A (ConA) Alexa Fluor 633
(Molecular ProbesTM; 40 min incubation) for eDNA and EPS visualisation
respectively. CLSM imaging of the bioﬁlm formation and bioﬁlm disruption
assays was performed using an Olympus FV1000 CLSM. CLSM imaging of
the bioﬁlm components (SYPRO® Ruby Bioﬁlm Matrix stain, TOTO-1, ConA)
and antibiotic potentiation assays was achieved using a Leica SP5 CLSM.
The CLSM images were achieved with an x63 lens (oil), a step size of
0.7 µm, line averaging of 2 and with simultaneous scanning (See
supplementary information for the excitation and emissions ranges of
the stains used in this study). CLSM images were processed using Imaris
software (Bitplane, Concord, MA, USA) as maximum intensity images. The
ﬂuorescence intensities from the CLSM bioﬁlm images achieved with ConA
and TOTO-1 were compiled from the Imaris programme.
COMSTAT image analysis
CLSM z-stack images were analysed using COMSTAT image analysis
software for quantiﬁcation of three-dimensional bioﬁlm structures through
measurement of bioﬁlm volume, surface roughness and bioﬁlm depth.41
Semi-quantiﬁcation of planktonic bacteria
The supernatant removed from the bioﬁlms was placed into a 96-well plate
and centrifuged at 3000×g for 10 min. The supernatant was then removed
and the cell pellets re-suspended in 100 μl of PBS, after which 1 μl of crystal
violet (0.5% w/v in PBS) was added into each well and the OD595 measured
to quantify the total biomass (live and dead) of planktonic cells.
Transwell® bioﬁlm diffusion studies
Overnight cultures of P. aeruginosa NH57388A were adjusted to 107 cfu
ml−1, and 0.1 ml of culture together with 0.2 ml of MH broth were added to
the 6.5 mm Transwell® (3.0 µm pore size; Corning) upper donor well, while
1 ml of MH broth was added into the lower acceptor well. The Transwell®
plate was then placed on a rocker at 20 rpm at 37 °C for 24 h. After growth,
the supernatant was removed from the donor well and 100 µl of MH (±0.5,
2, 6% OligoG) was added and incubated for a further 4 h. The supernatant
was again removed and the bioﬁlms rinsed twice in deionised water,
before moving the donor Transwells® to a new acceptor well containing
600 µl of deionised water. Then 140 µl of 0.007% negatively-charged
FluoSpheres (Carboxylate-modiﬁed Microspheres, 0.2 µm; Molecular Pro-
besTM) in distilled water were placed into each donor well and after 1 h
incubation, 100 µl of distilled water was removed from the acceptor well
and placed into a Grenier glass-bottom 96-well black plate for ﬂuorescence
reading. A Fluostar Omega Microplate Reader was used to measure end-
point ﬂuorescence (excitation 488 nm/emission 520 nm). Readings were
also taken at the 2 h incubation interval.
Molecular dynamics (MD) simulations of calcium, DNA and OligoG
CF-5/20 interactions
MD simulations were all run on the High Performance Wales Super-
computer (www.hpcwales.co.uk; Supporting Information). Sequences were
generated using BIOVIA Discovery Studio® 2017 software (BVS). Alginate
oligosaccharides were derived from the crystal structure of the molecule
(PDB ID 1J1N4) and converted into 16 repeat units using BVS and
elongated to 16 residues; correspond to the DPn of the OligoG used in the
in vitro experiments. Two, 15 bp DNA sequences were generated to
represent a double strand, selected from the genomes of P. aeruginosa;75
pseudomonal DNA sequences were selected to ensure their G:C ratios
were representative of P. aeruginosa as a whole (66.6%).
FTIR analysis of interactions of OligoG with DNA and Ca2+
FTIR analysis was performed on samples containing OligoG, Ca2+ ion
solution (1000 ppm; Cole Parmer WZ-27502-59) and DNA (170 µg/ml; >
90% at 50 kB: Promega G3041). All samples were vortexed, centrifuged at
1000×g for 30 s, before being incubated at 37 °C for 30min on a plate-
shaker. Five µl of each sample was then pipetted onto 96-well silicon plates
(Bruker Optics Inc., Billerica, MA). Following drying at room temperature for
1 h, high-throughput FTIR analysis was performed using a Bruker Vertex 70
with HTS-XT attachment and a DTGS detector (Bruker). Three replicates of
each sample were analysed where infrared spectra were obtained and
processed using the in-built tools and algorithms in OPUS 7.5. Spectra
were vector-normalised, baseline-corrected using the automatic “rubber-
band” correction.
Isothermal titration calorimetry
Buffer solutions were prepared by dissolving 5.84 g of NaCl, 4.19 g of
MOPS, and 0.11 or 0.55 g of CaCl2 in deionised water, adjusting the pH to
7.0 (Hanna Instruments pH210 microprocessor pH metre with a VWR
simple junction gel universal combined pH/reference electrode) using an
aqueous solution of sodium hydroxide, and making up the solution to 1 l.
OligoG solutions were prepared by dissolving 20mg of OligoG in 1ml of
the required buffer to obtain a solution of 101mM OligoG (concentration
in terms of monomeric units). DNA stock solutions were prepared by
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dissolving ~ 0.1 g ﬁsh sperm (FS) DNA in 10ml buffer. These solutions were
dialysed (MWCO 3.5 kDa) overnight against half a litre of buffer and the
DNA concentration was determined spectrophotometrically (JASCO
V630 spectrophotometer) using an extinction coefﬁcient of 12800M−1
cm−1 at 260 nm.76 The stock solution was diluted as required to prepare
1mM and 10mM solutions of DNA. For all experiments, other buffer
components used were 100mM NaCl and 20mM MOPS pH 7.0.
Calorimetric titrations were carried out at 37 °C on a MicroCal PEAQ-ITC
microcalorimeter (Malvern Instruments Ltd). The instrument was operated
by applying a reference power of 10 µcal/s, in high feedback mode, stirring
the sample cell contents at 750 rpm, with a pre-injection initial delay of
60 s. All experiments involved an initial injection of 0.4 µl in 0.8 s followed
by 12 further injections of 3.0 µl in 6.0 s into the calorimeter sample cell.
Injections were spaced by at least 150 s to allow full recovery of the
baseline. Raw data was treated using MicroCal PEAQ-ITC Analysis
Software (1.0.0.1259) to generate integrated heat effects per injection
(ΔQ). Molar heat effects per injection (ΔH) were calculated using Excel
(Microsoft).
Statistical analysis
Statistical software (Minitab v.14; Minitab, State College, PA) was used for
all statistical analyses presented. Parametric data was analysed using T-test,
while non-parametric data was analysed using Mann–Whitney test to
determine signiﬁcant differences for pair-wise comparisons. A P value of
<0.05 was considered statistically signiﬁcant.
Data availability
Data generated and analysed during this study are included in this
published article and its Supplemental information ﬁle. Additional details
available upon reasonable request.
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